Barclays
SLN icon

Barclays’s Silence Therapeutics SLN Stock Holding History

Barclays’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.14M Buy
195,958
+192,540
+5,633% +$2.34M ﹤0.01% 2549
2026
Q2 		$37.5K Buy
3,418
+481
+16% +$3.38K ﹤0.01% 4408
2026
Q1 		$15.5K Sell
2,937
-2,128
-42% -$11.7K ﹤0.01% 4627
2025
Q4 		$30.8K Sell
5,065
-2,071
-29% -$13.3K ﹤0.01% 4817
2025
Q3 		$37K Buy
7,136
+101
+1% +$561 ﹤0.01% 4838
2025
Q2 		$40.8K Buy
7,035
+181
+3% +$776 ﹤0.01% 4734
2025
Q1 		$19.3K Buy
6,854
+728
+12% +$3.56K ﹤0.01% 4797
2024
Q4 		$42.1K Buy
6,126
+2,793
+84% +$36K ﹤0.01% 4791
2024
Q3 		$60.6K Sell
3,333
-2,237
-40% -$41.6K ﹤0.01% 4703
2024
Q2 		$106K Hold
5,570
– – ﹤0.01% 3879
2024
Q1 		$120K Buy
+5,570
New +$121K ﹤0.01% 4366

Other funds holding SLN

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57.1B AUM 43.46% 1-Year Est. Return
Parallel Advisors
Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return

Barclays's SLN Position: Q3 2026 in Review

Barclays increased its Silence Therapeutics (SLN) stake by 5,633% in Q3 2026, buying an estimated $2.34M and bringing the position to 195,958 shares worth $2.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2549.

Barclays first reported a position in SLN in Q1 2024 and has held it in 11 quarters since. 16 funds tracked by Wall St. Rank hold SLN as of Q3 2026.

  • Barclays held 195,958 shares of Silence Therapeutics worth $2.14M as of Q3 2026.
  • Barclays bought 192,540 Silence Therapeutics shares in Q3 2026, an estimated $2.34M.
  • Silence Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2549 holding.
  • Barclays first reported a position in Silence Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • 16 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.